RTW Investments, a biotech-focused fund, purchased 11.8 million shares of Tango Therapeutics for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of AUM. The purchase comes as TNGX stock has surged 840% over the past year. The investment reflects confidence in Tango's lead candidate vopimetostat and upcoming clinical data for MTAP-deleted cancers, with the company well-funded through 2028.

Oorja Bio, a new clinical-stage biopharmaceutical company, announced a $30 million Series A funding round from Westlake BioPartners to develop ORJ-001, a first-in-class peptide therapeutic for idiopathic pulmonary fibrosis (IPF). The company has received FDA IND clearance and plans to initiate Phase 2 clinical trials in 2026. ORJ-001 is designed to restore alveolar epithelial type 2 (AEC2) cell function to promote lung repair and reverse fibrosis, addressing a significant unmet medical need in IPF treatment.

Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

Assembly Biosciences announced that its Chief Medical Officer, Anuj Gaggar, MD, PhD, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The company also highlighted positive Phase 1b data for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes treatment, with additional data selected for oral presentation and late-breaker poster presentation at ESCMID Global 2026.

Assembly Biosciences reported Q1 2026 financial results with cash reserves of $226.6 million, sufficient to fund operations into 2028. The company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 (licensed to Gilead) and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, with Phase 2 initiation expected in Q4 2026. Net loss was $9.1 million for the quarter.

Over 25 pharmaceutical companies are actively developing 30+ PARP inhibitor drugs in clinical trials, with major players including AstraZeneca, Gilead Sciences, and Nerviano Medical Sciences advancing promising candidates like Saruparib and NMS-293. The pipeline shows robust activity across multiple cancer indications including breast cancer, prostate cancer, and glioblastoma, with approximately 12+ drugs in early to mid-stage development. Recent developments include clinical collaborations and first-in-human trial updates from companies like Acerand Therapeutics and Synnovation Therapeutics.

DelveInsight's 2026 report reveals a robust rheumatoid arthritis pipeline with 75+ active players developing 80+ drugs across various clinical stages. The report highlights emerging therapies targeting novel pathways beyond traditional TNF inhibition, including JAK inhibitors, BTK inhibitors, and cell-based immunotherapies. Recent developments include positive Phase III results for Lynk Pharmaceuticals' zemprocitinib, FDA Fast Track designation for Artiva Biotherapeutics' AlloNK, and multiple licensing agreements signaling significant innovation in the RA treatment landscape.

U.S. stocks hit record highs as the S&P 500 and Nasdaq post their fourth consecutive weekly gains, driven by strong corporate earnings with 84% of S&P 500 companies beating estimates and 15.1% blended earnings growth. The Magnificent Seven tech giants—Microsoft, Alphabet, Amazon, Meta, and Apple—report earnings this week amid geopolitical tensions over U.S.-Iran talks and rising oil prices. The Fed meets Wednesday to decide on interest rates while investors monitor AI infrastructure spending and economic resilience.

Kailera Therapeutics, a spinoff of Hengrui Pharma's weight-loss drug portfolio, surged 63% on its Nasdaq debut, validating the 'NewCo' business model where Chinese drugmakers spin off promising pipelines into standalone companies. The IPO raised $625 million, the largest by a Chinese pharma company using this strategy. Hengrui retains a 9.8% stake now valued at ~$300 million and benefits from milestone payments and royalties.

Kymera Therapeutics will report Q1 2026 financial results on April 30, 2026. The company announced FDA Fast Track designation for KT-621, a first-in-class oral STAT6 degrader for moderate to severe asthma, with Phase 2b trial data expected in late 2027. Additionally, Gilead Sciences exercised its option to license KT-200, triggering a $45 million milestone payment to Kymera.

Nurix Therapeutics presented preclinical data at AACR 2026 demonstrating advances across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972. The data showcase the potential of targeted protein degradation therapies to overcome limitations of traditional inhibitors, with NRX-0305 showing 142% lifespan extension in resistant melanoma models and NRX-4972 achieving 60% survival in SCLC models compared to 0% for existing AURKA inhibitors.

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.